Compare NPWR & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NPWR | ANNX |
|---|---|---|
| Founded | 2010 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 285.1M | 334.1M |
| IPO Year | N/A | 2020 |
| Metric | NPWR | ANNX |
|---|---|---|
| Price | $2.18 | $5.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $3.50 | ★ $16.50 |
| AVG Volume (30 Days) | 897.9K | ★ 2.9M |
| Earning Date | 11-13-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 42.86 | N/A |
| 52 Week Low | $1.48 | $1.29 |
| 52 Week High | $11.83 | $5.66 |
| Indicator | NPWR | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 32.70 | 64.98 |
| Support Level | $2.12 | $5.04 |
| Resistance Level | $2.28 | $5.48 |
| Average True Range (ATR) | 0.16 | 0.29 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 9.98 | 50.00 |
NET Power Inc is a clean energy technology company that has developed a novel power generation system, which it refers to as the NET Power Cycle, designed to produce clean, reliable, and low-cost electricity from natural gas while capturing virtually all atmospheric emissions. The company's business model is to license its technology to customers and enable them to build, own, and operate facilities that utilize the Net Power Cycle. It has conducted a successful demonstration of its technology at the La Porte Demonstration Facility and is developing a utility-scale power plant in Texas named Project Permian.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.